Average Sales Price Creates Inflationary Pressure, Former CMS Head Says
Executive Summary
The use of average sales price for reimbursement of Medicare Part B-covered drugs puts inflationary pressure on drug prices, former Centers for Medicare & Medicaid Services Administrator Thomas Scully said
You may also be interested in...
End Of Aranesp, Procrit Pricing War Illustrates Inflationary Impact Of ASP
Pricing constraints created by changes in Medicare Part B reimbursement may mean that segment growth will be the key driver for erythropoietin products going forward
End Of Aranesp, Procrit Pricing War Illustrates Inflationary Impact Of ASP
Pricing constraints created by changes in Medicare Part B reimbursement may mean that segment growth will be the key driver for erythropoietin products going forward
Average Sales Price Final Rule Includes PhRMA’s Estimation Method
The methodology for estimating drug price concessions when submitting average sales prices for Medicare Part B will follow a proposal made by drug manufacturers in comments to the interim final rule